Idactamab INT-001 represents the exciting medicinal method for combating certain blood-related cancers. This particular antigen-binding protein demonstrates an distinct mode of effect, mainly targeting CD38, a exterior molecule expressed commonly on various hematopoietic populations. Ongoing clin… Read More

Lirilumab, a novel anti-cancer antibody targeting LAG-3, represents a significant step in oncology. Its evolution began with early studies demonstrating LAG-3's role in disease progression. Preclinical models suggested that blocking LAG-3 could enhance T-cell response and result in remission. Ear… Read More

Emicizumab, referred to as ART-101 is embodying a crucial advancement in treating these genetic disorder. This groundbreaking drug functions as a prothrombin molecule, mimicking factor VIII, a protein often lacking in patients with this condition. Unlike current factor therapies , emicizumab deli… Read More

Mitapivat, a novel medicinal agent, represents a promising development in the management of blood cell disorders such as pyruvate kinase deficiency (PKD). This unique drug functions as a potent PKR, boosting its activity and, consequently, modulating erythropoiesis. Its mode of operation is belie… Read More